Plasma Brain Natriuretic Peptide to Detect Preclinical Ventricular Systolic or Diastolic Dysfunction
- 29 June 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 109 (25) , 3176-3181
- https://doi.org/10.1161/01.cir.0000130845.38133.8f
Abstract
Background— Preclinical systolic or diastolic dysfunction is associated with increased morbidity and mortality. We postulated that plasma brain natriuretic peptide (BNP) might serve as a biomarker for preclinical ventricular dysfunction (PCVD) but that the discriminatory values for BNP may vary with age and sex.Keywords
This publication has 21 references indexed in Scilit:
- Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the CommunityCirculation, 2003
- Burden of Systolic and Diastolic Ventricular Dysfunction in the CommunityJAMA, 2003
- Retrospective analysis of thecost-effectiveness of using plasmabrain natriuretic peptide inscreening for left ventricularsystolic dysfunction in the general populationJournal of the American College of Cardiology, 2003
- Plasma Natriuretic Peptides for Community Screening for Left Ventricular Hypertrophy and Systolic DysfunctionJAMA, 2002
- Radioactive 133-Xenon Gas-Filled Balloon to Prevent RestenosisCirculation, 2002
- Mitral Ratio of Peak Early to Late Diastolic Filling Velocity as a Predictor of Mortality in Middle-Aged and Elderly AdultsCirculation, 2002
- Ethical considerations in the provision of controversial screening testsArchives of Family Medicine, 1997
- History of the Rochester Epidemiology ProjectMayo Clinic Proceedings, 1996
- Preventive Health Services in AdultsNew England Journal of Medicine, 1994
- Ruling Out or Ruling In Disease with the Most sensitiue or Specific Diagnostic TestMedical Decision Making, 1994